Annexon, Inc. · NASDAQ:ANNX

Annexon — Technical Presentation (May 2025)

4 slides from Annexon's technical presentation, May 2025

1. Slide 1: Tanruprubart Improves Health-Related Quality of Life in Patients With Guillain-Barré Syndrome Compared to Placebo

   [Poster 338]: Tanruprubart Improves Health-Related Quality of Life in Patients With Guillain-Barré Syndrome Compared to Placebo Glenn Morrison, MSc, PhD VP, Clinical Development Annexon Biosciences Tanruprubart (ANX005) is investigational and has not been approved for any indication in any jurisdict

2. Slide 2: Rationale

   Rationale • GBS is a rare, rapidly progressive, life-threatening neuromuscular emergency that can affect anyone, at anytime, and often requires prolonged hospitalization and intensive care1  Following exposure to an infectious agent, activation of C1q and the classical complement system by antibodi

3. Slide 3: Results: Consistently Better Outcomes in Tanruprubart 30mg/kg Arm vs. Placebo

   Results: Consistently Better Outcomes in Tanruprubart 30mg/kg Arm vs. Placebo Significantly more patients reported no problems in functional EQ-5D-5L domains Mobility Self care (washing and dressing) Usual activities 50 50 50 45 45 45 Proportion reporting no problems (%) Proportion reporting no prob

4. Slide 4: Conclusions

   Conclusions [Poster 338] Participants who received tanruprubart 30 mg/kg were able to rapidly gain independence across a range of basic and instrumental ADLs compared to placebo EQ-5D-5L data correlate with rODS data, demonstrating significant and sustained improvements across all functional health

Annexon — Technical Presentation (May 2025) on 6ix